A leap towards personalised therapy of acute lung injury

Eur Respir J. 2022 Dec 15;60(6):2201808. doi: 10.1183/13993003.01808-2022. Print 2022 Dec.

Authors

Martin Witzenrath^{1

2}, Tobias Welte^{2

3}

Affiliations

¹ Charité-Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany martin.witzenrath@charite.de.
² German Center for Lung Research (DZL).
³ Hannover Medical School, Department of Respiratory Medicine, Hannover, Germany.

PMID: 36522140
DOI: 10.1183/13993003.01808-2022

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acute Lung Injury* / therapy
COVID-19*
Humans
Imatinib Mesylate
Immunomodulation
Precision Medicine

Substances

Imatinib Mesylate